Indication intelligence, analysis and sector perception

Cellectis (Paris: ALCLS) (NASDAQ:CLLS)) Enters into new agreement with CELLforCURE

January 20, 2016 9:44am

... for the cGMP Manufacturing of UCART123 for Hematological Malignancies

Cellectis has entered into a new agreement for the cGMP manufacturing of UCART123 clinical batches, Cellectis’ lead product candidate.

CELLforCURE is an LFB group company and the largest industrial facility for clinical and commercial production of innovative cell therapies in Europe.

Peripheral Blood Monoculear Cells from healthy donors are transduced and genetically edited with Cellectis’ TALEN® technology to seek and destroy cancer cells.

The Bottom Line: This approach could lead to a drug that … could be cost-effective, made readily available - “off the shelf” - to broad patient populations in hospitals without need for local CAR-T processing facilities and easily distributed across all geographies.

CLLS closed at $22.17 and is DOWN pre-open -$0.26. it seems that this release is NOT resonating!

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

6 hours 51 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.